| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Income and revenues | 38,392 | - |
| Business development and deal related costs | 7,212 | - |
| Research and development expenses | 1,431 | - |
| Depreciation of property and equipment | 8 | - |
| Other general and administrative expenses | 18,462 | - |
| Amortization of intangible assets | 2,077 | - |
| Gains on acquisitions | 18,004 | - |
| Change in fair value of derivatives related to castle creek | -10 | - |
| Interest expense | 10,004 | - |
| Other income, net-Operating Segments | 8,466 | - |
| Income tax expense | 49 | - |
| Net income (loss) | 25,609 | 11,558 |
| Adjustment for income from eir method purchased receivables | 627 | -3,935 |
| Stock-based compensation expense | 5,358 | 3,588 |
| Gains on acquisitions | 18,004 | - |
| Gain on sale of equity securities | 3,663 | 5,173 |
| Income tax expense | 49 | - |
| Common stock contribution to 401 | 141 | 141 |
| Amortization of intangible assets | 2,077 | 1,199 |
| Depreciation | 8 | 6 |
| Accretion of long-term debt discount and debt issuance costs | 1,136 | 749 |
| Non-cash lease expense | -47 | -31 |
| Change in fair value of equity securities | 1,230 | - |
| Change in fair value of available-for-sale debt securities classified as cash equivalents | 49 | 49 |
| Change in fair value of derivatives | -10 | 5 |
| Trade and other receivables, net | 1,187 | -22 |
| Prepaid expenses and other assets | -1,839 | -1,715 |
| Accounts payable and accrued liabilities | -3,248 | -387 |
| Operating lease liabilities | -268 | -219 |
| Unearned revenue recognized under units-of-revenue method | -978 | -671 |
| Net cash provided by (used in) operating activities | 8,372 | 8,668 |
| Net cash, cash equivalents, and restricted cash acquired in acquisition-Turnstone Biologics Corp | 3,943 | - |
| Net cash, cash equivalents, and restricted cash acquired in acquisition-Hillevax Inc | 46,832 | - |
| Payments of consideration under rpas, aaas, and cppas | 8,000 | 8,000 |
| Receipts under rpas, aaas, and cppas | 3,139 | 2,039 |
| Payment for bioinvent contract-based intangible asset | 20,725 | 20,614 |
| Payment of contingent consideration related to kinnate ip asset | 550 | - |
| Purchase of equity securities | 99 | 99 |
| Sale of equity securities | 6,999 | - |
| Net cash provided by investing activities | 31,539 | -26,674 |
| Principal payments - debt | 10,598 | 5,065 |
| Debt issuance costs and loan fees paid in connection with long-term debt | 80 | 80 |
| Payment of preferred stock dividends | 4,104 | 2,736 |
| Repurchases of common stock | 2,395 | 2,370 |
| Proceeds from exercise of options and other share-based compensation | 3,422 | 896 |
| Taxes paid related to net share settlement of equity awards | 2,019 | 570 |
| Net cash used in financing activities | -15,774 | -9,925 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 24,137 | -27,931 |
| Cash and cash equivalents at beginning of period | 106,416 | - |
| Cash and cash equivalents at end of period | 130,553 | - |
XOMA Royalty Corp (XOMA)
XOMA Royalty Corp (XOMA)